Heparin, Low-Molecular-Weight
"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Concept/Terms
Heparin, Low-Molecular-Weight- Heparin, Low-Molecular-Weight
- Heparin, Low Molecular Weight
- LMWH
- Low Molecular Weight Heparin
- Low-Molecular-Weight Heparin
Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".
Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".
This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in Harvard Catalyst Profiles by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 5 | 1 | 6 |
| 1999 | 7 | 5 | 12 |
| 2000 | 3 | 2 | 5 |
| 2001 | 4 | 4 | 8 |
| 2002 | 5 | 5 | 10 |
| 2003 | 6 | 3 | 9 |
| 2004 | 5 | 6 | 11 |
| 2005 | 6 | 5 | 11 |
| 2006 | 2 | 4 | 6 |
| 2007 | 2 | 6 | 8 |
| 2008 | 5 | 6 | 11 |
| 2009 | 2 | 1 | 3 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 5 | 8 |
| 2012 | 2 | 5 | 7 |
| 2013 | 2 | 2 | 4 |
| 2014 | 5 | 4 | 9 |
| 2015 | 1 | 0 | 1 |
| 2016 | 5 | 4 | 9 |
| 2017 | 3 | 1 | 4 |
| 2018 | 4 | 5 | 9 |
| 2019 | 2 | 10 | 12 |
| 2020 | 7 | 11 | 18 |
| 2021 | 5 | 5 | 10 |
| 2022 | 1 | 14 | 15 |
| 2023 | 2 | 7 | 9 |
Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.
-
Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review. J Thromb Haemost. 2024 Feb; 22(2):423-429.
-
Is There a Role for Anti-factor Xa Activity Assay in Venous Thromboembolism Prophylaxis Management Among Orthopaedic Trauma Patients? Systematic Review and Meta-analysis. J Orthop Trauma. 2023 09 01; 37(9):e368-e376.
-
Low-molecular-weight heparin is superior to unfractionated heparin in lowering the risk of venous thromboembolism after traumatic lower extremity amputation. Surgery. 2023 10; 174(4):1026-1033.
-
Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist. 2023 07 05; 28(7):555-564.
-
Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis. JAMA Netw Open. 2023 07 03; 6(7):e2325283.
-
Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. JAMA. 2023 06 13; 329(22):1924-1933.
-
Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis. Thromb Res. 2023 07; 227:8-16.
-
Efficacy of Postpartum Pharmacologic Thromboprophylaxis: A Systematic Review and Meta-analysis. Obstet Gynecol. 2023 04 01; 141(4):697-710.
-
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med. 2023 01 19; 388(3):203-213.
-
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2023 02; 21(1):55-62.